Bright Minds Biosciences : Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2024 and 2023 (Expressed in Canadian Dollars) - Form 6-K

Bright Minds Biosciences Inc.


Condensed Interim Consolidated Financial Statements


For the six months ended March 31, 2024 and 2023





...

Related Keywords

Vancouver ,British Columbia ,Canada ,New York ,United States ,Australia ,Delaware ,United Kingdom ,British ,Canadian ,Ian Mcdonald ,Karl Deisseroth ,Company On ,Units Of The Company ,Bright Minds Bioscience Pty Ltd ,Pfws Of The Company ,Nasdaq ,International Financial Reporting Standards ,Board Of Trustees ,Directors Of The Company ,Canadian Stock Exchange ,International Accounting Standards Board ,International Accounting Standard ,Company See ,Bright Minds Biosciences ,Bright Minds Biosciences Inc ,Canadian Dollars ,Interim Consolidated Statements ,Condensed Interim Consolidated Financial ,Minds Biosciences ,Business Corporations Act ,Georgia Street ,Corporations Act ,Bright Minds Bioscience Pty ,Each Warrant ,Payment Shares ,National Policy ,Initial Public Offerings ,Black Scholes ,Chief Medical Officer ,Key Management ,Patent Rights ,Technical Information ,Net Sales ,Sublicensee Revenue ,New York United States ,Right Of Use Assets ,Lease Liabilities ,Lease Liability Continuity ,